A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

NCT06279364 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

524

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: SKB264
DRUG: Paclitaxel
DRUG: Nab-paclitaxel
DRUG: Capecitabine
DRUG: Eribulin
DRUG: Carboplatin

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.